CACCIOLA, Irene
 Distribuzione geografica
Continente #
EU - Europa 1.499
NA - Nord America 1.382
AS - Asia 436
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
OC - Oceania 1
Totale 3.324
Nazione #
US - Stati Uniti d'America 1.380
IE - Irlanda 487
SE - Svezia 412
IT - Italia 281
CN - Cina 234
SG - Singapore 153
DE - Germania 74
UA - Ucraina 63
FI - Finlandia 51
PL - Polonia 38
GB - Regno Unito 31
BE - Belgio 26
IN - India 26
FR - Francia 12
ID - Indonesia 10
RU - Federazione Russa 9
CZ - Repubblica Ceca 5
VN - Vietnam 5
CL - Cile 3
IR - Iran 3
CA - Canada 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
AT - Austria 1
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CH - Svizzera 1
EG - Egitto 1
ES - Italia 1
HU - Ungheria 1
JP - Giappone 1
KZ - Kazakistan 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
Totale 3.324
Città #
Dublin 487
Chandler 294
Nyköping 279
Jacksonville 146
Singapore 127
Messina 120
Beijing 84
Ann Arbor 75
Ashburn 73
Princeton 67
Medford 62
Des Moines 50
Dearborn 44
Cambridge 40
Warsaw 31
Boardman 29
Jinan 24
Brussels 23
Los Angeles 19
Munich 19
Rosolini 19
Woodbridge 19
Helsinki 15
Nanjing 15
Rome 15
Hyderabad 14
New York 14
San Mateo 12
Wilmington 12
Hebei 11
Seattle 11
Catania 10
Jakarta 10
Pune 10
Shenyang 10
Avola 9
Houston 9
Tianjin 9
Haikou 8
Bremen 7
Pachino 7
Fuzhou 5
Guangzhou 5
Hangzhou 5
Palermo 5
Taizhou 5
Zhengzhou 5
Brno 4
Changsha 4
Dong Ket 4
Falls Church 4
Nanchang 4
Radomsko 4
Shanghai 4
Antwerp 3
Auburn Hills 3
Caltagirone 3
Hefei 3
Lanzhou 3
New Haven 3
Ningbo 3
Qingdao 3
Redwood City 3
Tappahannock 3
Washington 3
Ardabil 2
Athens 2
Bologna 2
Chengdu 2
Clearwater 2
Cradley 2
Culver City 2
Frontone 2
Jiaxing 2
Lamézia 2
Leawood 2
Mannheim 2
Marlow 2
Milan 2
Norwalk 2
Nuremberg 2
Scandicci 2
Sortino 2
Taiyuan 2
Viagrande 2
Villejuif 2
Yicheng 2
Zagreb 2
Alcamo 1
Alexandria 1
Almaty 1
Augusta 1
Baku 1
Bracknell 1
Carrara 1
Chicago 1
Chisinau 1
Edinburgh 1
Fiumefreddo di Sicilia 1
Hanoi 1
Totale 2.488
Nome #
Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography 109
Lack of the NS5B S282T mutation in HCV isolates from liver tissue of naive patients with HCV genotype-1b infection. 106
Atrial fibrillation in patients with cirrhosis 101
NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C 84
Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases 83
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 80
Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C 69
Elective endoscopic variceal ligation is not a risk factor for bacterial infection in patients with liver cirrhosis 68
Fibroscan: a new non-invasive method for evaluation of liver dysfunction in Turner syndrome 67
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 67
Oscillazione dei livelli di viremia in soggetti portatori cromici asintomatici di infezione da virus B. Dati preliminari 65
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. 64
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection 63
Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. 62
TT virus has a ubiquitous diffusion in human body tissues: analyses of paired serum and tissue samples. 61
Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. 61
Behaviour of occult HBV infection in HCV-infected patients under treatment with direct-acting antivirals 61
The HCV Sicily Network: A web-based model for the management of HCV chronic liver diseases 61
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. 61
INTRAHEPATIC HDV RNA, HBV DNA, AND HBV RNAS QUANTIFICATIONS REVEAL SUPPRESSION OF HBV PREGENOME RNA PRODUCTION WITH MAINTENANCE OF PRES/S TRNSCRITION IN HDV/HBV CO-INFECTED PATIENTS 60
Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy 60
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. 59
Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease 58
NS3 Q80K Polymorphism in viral isolates from Liver Tissues and serum samples of naive HCV genotype 1a Patients 57
Infezione occulta da virus dell’epatite B in pazienti con epatite cronica virus con correlata valutazione istologica 54
Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care 54
Oscillazione dei livelli di viremia in soggetti portatori cronici asintomatici di infezione da virus b. Dati preliminari 53
Molecular analyses of TT virus in paired and tissue samples from 150 patients with either hepatic or non-hepatic disease 52
Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. 51
Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection 51
Impact of Occult Hepatitis B Virus Infection on the Outcome of Chronic Hepatitis C. 51
Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy 49
Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. 48
PREVALENCE OF BACTERIAL RESISTANCE IN CIRRHOTIC PATIENTS WITH BACTERIAL INFECTION: A PRELIMINARY REPORT 48
Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B 48
Strain endocardico longitudinale tra pazienti cirrotici di classe A e B al punteggio di Child-Pugh 48
Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications. 48
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience 48
Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity 48
Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study 47
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease 47
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study 47
Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis 47
Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. 45
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. 45
Erectile dysfunction in compensated liver cirrhosis 45
Fever and rhomboid target lesion in decompensated cirrhosis 44
Mucocutaneous toxicity during simeprevir treatment for hepatitis C. A single institution, retrospective case series 44
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 44
Cirrhotic Patients with Bacterial Infection and Negative Cultures Have a More Advanced Disease and an Increased Short-Term Mortality Rate 44
New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress 43
Occult hepatitis B virus infection 38
Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. 38
Dermatiti iatrogene in corso di trattamento dell’epatopatia HCV-correlata con simeprevir 37
Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound‑detected liver nodules 37
Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance 36
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 33
The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study 29
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis 28
High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease 25
Effects of Proton Pump Inhibitors in Cirrhotic Patients: What Do We Really Know? 24
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 23
A Keynesian perspective on the health economics of kidney transplantation would strengthen the value of the whole organ donation and transplantation service 23
null 22
Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis 21
Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes 20
null 19
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 18
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort 16
Assessing Genomic Mutations in SARS-CoV-2: Potential Resistance to Antiviral Drugs in Viral Populations from Untreated COVID-19 Patients 14
Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients 14
RESIST-HCV criteria to monitor progression of low-risk esophageal varices in patients with compensated cirrhosis after HCV eradication. The SIMPLE study 10
Health economics aspects of kidney transplantation in Sicily: a benchmark analysis on activity and estimated savings 8
Totale 3.513
Categoria #
all - tutte 16.638
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.638


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020271 0 0 0 0 6 48 42 27 9 81 51 7
2020/2021408 35 4 84 16 48 30 21 48 39 45 22 16
2021/2022481 13 53 14 14 36 4 52 11 7 66 65 146
2022/20231.347 81 162 73 89 86 127 32 77 556 7 37 20
2023/2024340 27 61 20 36 31 44 7 10 3 44 18 39
2024/2025294 30 27 44 118 75 0 0 0 0 0 0 0
Totale 3.513